BriaCell Therapeutics Corp.BCTXNASDAQ
Loading
R&D Expense Growth Under PressureDecelerating
Percentile Rank41
Year-over-Year Change
Year-over-year research & development expense growth
Percentile
P41
Within normal range
vs 3Y Ago
-0.8x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | -4.88% |
| Q3 2025 | 41.99% |
| Q2 2025 | -16.43% |
| Q1 2025 | 63.83% |
| Q4 2024 | -17.59% |
| Q3 2024 | -41.17% |
| Q2 2024 | -7.65% |
| Q1 2024 | 21.05% |
| Q4 2023 | 33.61% |
| Q3 2023 | 31.29% |
| Q2 2023 | 27.20% |
| Q1 2023 | -4.30% |
| Q4 2022 | 6.43% |
| Q3 2022 | 41.52% |
| Q2 2022 | 32.57% |
| Q1 2022 | 96.92% |
| Q4 2021 | 51.52% |
| Q3 2021 | -48.84% |
| Q2 2021 | 595.94% |
| Q1 2021 | 31.33% |
| Q4 2020 | -67.54% |
| Q3 2020 | 68.33% |
| Q2 2020 | -76.65% |
| Q1 2020 | 22.05% |
| Q4 2019 | -24.47% |
| Q3 2019 | 24.92% |
| Q2 2019 | -32.25% |
| Q1 2019 | 57.11% |
| Q4 2018 | -18.86% |
| Q3 2018 | 82.58% |
| Q2 2018 | -11.90% |
| Q1 2018 | 63.58% |
| Q4 2017 | -46.82% |
| Q3 2017 | 13.51% |
| Q2 2017 | 257.83% |
| Q1 2017 | -18.80% |
| Q4 2016 | -68.57% |
| Q3 2016 | 3087.35% |
| Q2 2016 | -33.02% |
| Q1 2016 | -73.71% |